[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

A Prospective, Multicenter, Randomized, Investigator-Masked, Active-Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Study Overview

• Status: Recruiting
• Conditions: Ocular Hypertension; Glaucoma Open-Angle Primary
• Intervention / Treatment: Drug: TFC-003; Drug: TFC-003-R1; Drug: TFC-003-R2+TFC-003-R3

• Study Type: Interventional
• Enrollment (Estimated): 188
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Kukje Pharma Kukje Pharma; Email: kj341010@kukjepharm.co.kr

Study Locations

• South Korea
  • Seongnam, South Korea
    • Recruiting
    • Kukje Pharma
    • Contact: Kukje Pharma

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female adults aged ≥19 years at the time of informed consent.
2. Diagnosis of primary open-angle glaucoma or ocular hypertension.

3. At the screening visit, subjects who meet any of the following:

   • history of or current use of triple therapy, or
   • history of or current use of dual therapy (dorzolamide and a topical beta-blocker), or
   • inadequate IOP control despite current treatment, and who, in the investigator's judgment, have not achieved target IOP based on the degree of optic nerve damage and may benefit from additional IOP reduction with triple therapy.

4. Completion of an appropriate washout period for prior glaucoma medications before the randomization visit (based on the longest washout period among the components of prior medications):

   - Parasympathomimetics, oral or topical carbonic anhydrase inhibitors: 5 days

   - α-agonists: 14 days (brimonidine: 28 days)

   • β-antagonists, prostaglandin analogues: 28 days
   • Rho-kinase inhibitors: 28 days
5. Mean intraocular pressure (IOP) ≥21 mmHg in either eye at 8:30 AM (±1 hour) at the randomization visit (same eye as the study eye).
6. Ability to understand and voluntarily sign the informed consent form.

Exclusion Criteria:

1. Subjects with any of the following comorbidities or conditions:

1. Central visual field defect with mean deviation (MD) ≤ -25 dB on visual field testing.
2. Chronic, recurrent, or severe inflammatory ocular disease (e.g., scleritis, uveitis, or herpetic keratitis).
3. Best-corrected visual acuity (BCVA) < 0.25 (Han Chun Suk visual acuity chart) at both screening and randomization visits.
4. Any condition that prevents reliable intraocular pressure (IOP) measurement.
5. Other ocular pathology that, in the investigator's opinion, precludes use of the investigational product (e.g., severe dry eye).
6. Conditions requiring additional topical or systemic IOP-lowering medications during the study.
7. Reactive airway disease, including bronchial asthma or history thereof, bronchospasm, or severe chronic obstructive pulmonary disease.
8. Sinus bradycardia, second- or third-degree atrioventricular block, overt heart failure, cardiogenic shock, sick sinus syndrome, or sinoatrial block.
9. Severe renal impairment (creatinine clearance <30 mL/min) or hyperchloremic acidosis.
10. Untreated pheochromocytoma.
11. Any severe disease that, in the investigator's judgment, renders the subject unsuitable for the study.

2. History of the following conditions or procedures (including surgery):

1. Ocular trauma or ocular surgery within 24 weeks prior to screening (cataract surgery performed >8 weeks prior is not excluded).
2. Ocular infection or ocular inflammation within 12 weeks prior to screening (within 8 weeks for simple conjunctivitis).
3. Ocular laser surgery within 12 weeks prior to screening.

3. Prior or concomitant medications:

1. Oral beta-blockers within 4 weeks prior to randomization.
2. Addition of antihypertensive agents that may affect IOP within 4 weeks prior to randomization (excluding beta-blockers; e.g., calcium channel blockers, ACE inhibitors), unless the regimen has been stable for at least 7 days prior to screening.
3. α-adrenergic agonists, MAO inhibitors, or antidepressants affecting norepinephrine transmission within 2 weeks prior to randomization.
4. Topical ocular or periocular corticosteroids within 2 weeks prior to randomization.
5. Systemic corticosteroids within 4 weeks prior to randomization.
6. Intravitreal or sub-Tenon corticosteroid injection within 24 weeks prior to randomization.

4. Subjects requiring contact lens use during the study period. 5. Known hypersensitivity, in the investigator's opinion, to any component of the investigational product or ophthalmic diagnostic eye drops.

6. Use of any investigational drug or device within 4 weeks prior to screening (subjects participating in non-interventional studies such as observational studies or PMS may be enrolled).

7. Pregnant or breastfeeding women. 8. Women and men of childbearing potential who are unwilling to use medically acceptable contraception or who plan pregnancy during the study period.

Acceptable contraception methods:

Hormonal contraceptives (oral, injectable, implantable, etc.) Intrauterine device (IUD) or intrauterine system (IUS) Surgical sterilization (e.g., vasectomy, hysterectomy, bilateral oophorectomy, bilateral salpingectomy) Sexual abstinence (only absolute abstinence is acceptable; periodic abstinence methods such as calendar, basal body temperature, ovulation methods, withdrawal, or barrier methods are not acceptable unless investigator-deemed strict abstinence is appropriate based on age, occupation, lifestyle, or sexual orientation)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TFC-003; TFC-003 will be administered as one drop into the affected eye(s) twice daily at approximately 8:30 AM and 8:30 PM (±1 hour).	Drug: TFC-003; TFC-003 will be administered as one drop into the affected eye(s) twice daily at approximately 8:30 AM and 8:30 PM (±1 hour).
Active Comparator: TFC-003-R1; TFC-003-R1 will be administered as one drop into the affected eye(s) twice daily at approximately 8:30 AM and 8:30 PM (±1 hour).	Drug: TFC-003-R1; TFC-003-R1 will be administered as one drop into the affected eye(s) twice daily at approximately 8:30 AM and 8:30 PM (±1 hour).
Active Comparator: TFC-003-R2+TFC-003-R3; TFC-003-R2 and TFC-003-R3 will be administered as one drop each into the affected eye(s) twice daily at approximately 8:30 AM and 8:30 PM (±1 hour) every day. The two eye drops (TFC-003-R2 and TFC-003-R3) will be administered at least 10 minutes apart.	Drug: TFC-003-R2+TFC-003-R3; TFC-003-R2 and TFC-003-R3 will be administered as one drop each into the affected eye(s) twice daily at approximately 8:30 AM and 8:30 PM (±1 hour) every day. The two eye drops (TFC-003-R2 and TFC-003-R3) will be administered at least 10 minutes apart.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison between the two groups in the mean change in diurnal intraocular pressure from baseline to Week 12 after 12 weeks of treatment with TFC-003 and TFC-003-R1.	All IOP measurements will be performed using the same Goldmann applanation tonometer. The study eye will be selected at baseline, and only IOP measurements from the selected study eye will be used for the efficacy analysis.	Baseline, 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
After 24 weeks of treatment with TFC-003 and TFC-003-R1, the two groups will be compared for each efficacy endpoint.	Mean change from baseline in diurnal intraocular pressure (IOP) at Weeks 4, 8, and 24.; Mean change from baseline in IOP measured at 8:30 AM (±1 hour) at Weeks 4, 8, 12, and 24.; Mean change from baseline in IOP measured at 10:30 AM (±1 hour) at Weeks 4, 8, 12, and 24.; Mean change from baseline in IOP measured at 4:30 PM (±1 hour) at Weeks 4, 8, 12, and 24.	Baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks

Collaborators and Investigators

• Sponsor: Kukje Pharma

Study record dates

Study Major Dates

• Study Start (Actual): December 9, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): June 1, 2027

Study Registration Dates

• First Submitted: June 17, 2026
• First Submitted That Met QC Criteria: June 17, 2026
• First Posted (Actual): June 23, 2026

Study Record Updates

• Last Update Posted (Actual): June 23, 2026
• Last Update Submitted That Met QC Criteria: June 17, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension
• Other Study ID Numbers: KJ-TFC-005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No